A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects With Anal Fissure

Trial Profile

A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects With Anal Fissure

Completed
Phase of Trial: Phase III

Latest Information Update: 21 May 2014

At a glance

  • Drugs Diltiazem (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Ventrus Biosciences
  • Most Recent Events

    • 12 Feb 2014 Primary endpoint 'Significant difference in change in pain intensity during or after defecation been treatment and placebo' has not been met, as reporrted by a Ventrus Biosciences media release.
    • 12 Feb 2014 Top-line results reported in a Ventrus Biosciences media release.
    • 30 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top